[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366552-105":59,"doc-detail-366552-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","differences-in-survival-outcomes-between-her2-low-and-her2-zero-breast-cancer-across-heterogeneous-hr-expression-patterns-a-realworld-study","Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns - A realworld study","","A real-world retrospective study evaluates how heterogeneous hormone receptor (HR) expression patterns influence survival in HER2-negative breast cancer. Using 648 patients treated between 2010 and 2023, researchers compare ER/PR-defined and single-HR-defined subgroups across HER2-low and HER2-zero categories with disease-free and overall survival as endpoints. Results indicate HER2-low aligns with more favorable survival overall and distinct prognostic effects within HR subgroups, including longer DFS for ER+/PR+/HER2-low versus single HR+/HER2-low. Findings support HR- and biomarker-informed treatment strategy refinement.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/differences-in-survival-outcomes-between-her2-low-and-her2-zero-breast-cancer-across-heterogeneous-hr-expression-patterns-a-realworld-study/366552/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/differences-in-survival-outcomes-between-her2-low-and-her2-zero-breast-cancer-across-heterogeneous-hr-expression-patterns-a-realworld-study/366552.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does this study address about HER2-negative breast cancer?","Question",{"text":113,"@type":114},"It investigates whether varying ER and PR expression patterns change survival outcomes in patients with HER2-negative breast cancer, comparing HER2-low versus HER2-zero subtypes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the study designed and who were included?",{"text":118,"@type":114},"The study is retrospective, including 648 HER2-negative breast cancer patients treated between 2010 and 2023, grouped into six ER/PR and single HR subgroups.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main survival findings comparing HER2-low and HER2-zero?",{"text":122,"@type":114},"In the overall population, HER2-low showed better disease-free survival and overall survival than HER2-zero, and HER2-low was an independent prognostic factor. The ER+/PR+/HER2-low subgroup also had longer DFS than the single HR+/HER2-low group.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366552,1790197989,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Zeng et al. World Journal of Surgical Oncology (2025) 23:331  \n[https://doi.org/10.1186/s12957-025-03962-4](https://doi.org/10.1186/s12957-025-03962-4)  \nWorld Journal of Surgical Oncology  \nRESEARCH Open Access  \nDifferences in survival outcomes between   HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a realworld study  \nYi Zeng 1, Pengfei Qian 1†, Guanhong Li 1† andYu Sun 1*  \nAbstract  \nIntroduction HER2-negative breast cancers can be further subclassified into HER2-low and HER2-zero subtypes. The DESTINY-Breast04 trial has established HER2-low as a research hotspot, with recent studies indicating superior survival rates in HER2-low patients than HER2-zero patients. The impact of heterogeneous hormone receptor (HR) expression patterns on HER2-negative breast cancer has not been comprehensively investigated. This study explored how varying ER and PR expression patterns affect survival rates in patients with HER2-negative breast cancer.  \nMethods This retrospective study comprised 648 HER2-negative breast cancer patients treated at our hospital between 2010 and 2023. Six subgroups were compared, including ER+/PR+/HER2-low, ER+/PR+/HER2-zero, single HR+/HER2-low, single HR/HER2-zero, ER-/PR-/HER2-low, and ER-/PR-/HER2-zero.  \nResult With disease-free survival and overall survival as primary endpoints, the cohort included 648 HER2-negative breast cancer patients. Compared to HER2-zero, HER2-low patients showed a higher proportion of ER positivity  \n(q = 0 . 016) . The ER+/PR + group exhibited a higher proportion of HER2-low, lower N stage, lower histological grade, and lower Ki-67%(p \u003C 0. 001), and were also more likely to achieve pCR after neoadjuvant therapy. In the overall population, HER2-low exhibited better survival outcomes. Compared to single HR+/HER2-low, ER+/PR+/HER2-low had longer DFS (p \u003C 0. 001) . HER2-low is an independent prognostic factor for survival outcomes in HER2-negative patients.  \nConclusion Our findings suggest that HER2-low breast cancer is associated with improved survival outcomes compared to HER2-zero breast cancer. HER2-low breast cancer exhibits different survival outcomes across different HR subgroups. These findings may guide future biomarker-driven treatment strategies in HER2-negative breast cancer. Keywords Breast cancer, HER2-low, Estrogen receptor, Progesterone receptor  \n†Pengfei Qian and Guanhong Li contributed equally to this work.  \n*Correspondence: Yu Sun [15089231312@163.com](15089231312@163.com)  \n1Department of Breast Surgery, The Affiliated Huizhou Hospital, Guangzhou Medical University, No.1 Xuebei Road, Huizhou, Guangdong 516000, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nZeng et al. World Journal of Surgical Oncology (2025) 23:331  \nIntroduction  \nBreast cancer remains the most prevalent malignancy among women globally [1]. Molecular subtyping based on immunohistochemical (IHC) profiles of estrogen receptor (ER), pro","cbCais9F6eU2phP5","https://ap.wps.com/l/cbCais9F6eU2phP5","pdf",1997515,17,"English","# Introduction\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What question does this study address about HER2-negative breast cancer?\",\"answer\":\"It investigates whether varying ER and PR expression patterns change survival outcomes in patients with HER2-negative breast cancer, comparing HER2-low versus HER2-zero subtypes.\"},{\"question\":\"How was the study designed and who were included?\",\"answer\":\"The study is retrospective, including 648 HER2-negative breast cancer patients treated between 2010 and 2023, grouped into six ER/PR and single HR subgroups.\"},{\"question\":\"What were the main survival findings comparing HER2-low and HER2-zero?\",\"answer\":\"In the overall population, HER2-low showed better disease-free survival and overall survival than HER2-zero, and HER2-low was an independent prognostic factor. The ER+/PR+/HER2-low subgroup also had longer DFS than the single HR+/HER2-low group.\"}]","Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns - A realworld study | PDF",1790166067,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/983056716b709f5322fb6274da39c176.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/338c090b39776dc1a2b7febebab5dece.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a2695a100b47be377b6a34ceee0576e.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74268b1dbc8ea307b22bbe4daf9d6b3d.webp",980,1306]